After a period of unsteady sales for its key COVID-19 products, Pfizer now sees COVID-related revenue volatility as “largely in the past.”  | The company benefited from higher-than-expected sales of ...

Eliquis, a blood thinner marketed in partnership with Bristol Myers Squibb, is Pfizer's largest revenue stream at the moment. It could begin competing with generic versions in the U.S. market in 2028, ...

Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/105.DozQrLpG.js ...

Drugmaker Pfizer posted a better-than-expected fourth-quarter profit on Thursday, helped by cost cuts it began last year as ...

Pfizer's adjusted EPS of $0.63 surpassed the expected $0.47 ... Cost reduction efforts culminated in a significant $3.59 ...

Pfizer reported strong 2024 profits Wednesday on the same day the Connecticut Attorney General’s office released a statement ...

Eligible Medicare beneficiaries can access Paxlovid at no cost until February 28, 2025, through a patient assistance program operated by the manufacturer, Pfizer. This initiative ensures that ...

Pfizer expects to sufficiently de-lever its balance sheet by ... driven primarily by fewer COVID-19 vaccinations globally as well as lower contracted doses. Fourth-quarter 2024 Paxlovid revenues of ...

This outlook includes expectations for COVID-19 product revenues to remain consistent with 2024, excluding a one-time $1.2 ...

Pfizer (PFE) stock is up today after the pharmaceutical company reported earnings for the fourth quarter of 2024. The company ...